Table 1.
Asthma control end points, baseline and during SMART therapy
| Rabe et al10 | Scicchitano et al11 | O'Byrne et al12 | Rabe et al14 | Vogelmeier et al15 | Kuna et al21 | Bousquet et al19 | Weighted averages | |
| N (SMART arm) | 354 | 947 | 925 | 1107 | 1067 | 1052 | 1151 | |
| Study duration | 6 months | 12 months | 12 months | 12 months | 12 months | 6 months | 6 months | N/A |
| Symptom-free days (%) | B: 29.6 | B: 9.8 | B: 23.1 | B: 9.2* | NA | B: 9.3 | B: 10.7 | B: 13.2 |
| T: 55.1 | T: 41.7 | T: 54 | T: 40.3* | T: 44.2 | T: 47.2 | T: 46.0 | ||
| As-needed reliever use inhalations/day) | B: 1.64 | B: 1.9 | B: 2.46 | B: 1.8 | B: 2.6 | B: 2.29 | B: 2.23 | B: 2.18 |
| T: 1.04 | T: 0.90 | T: 1.01 | T: 1.02 | T: 0.59† | T: 1.02 | T: 0.95 | T: 0.92 | |
| Reliever-free days (%) | B: 24.3 | B: 29.3 | B: 8.2 | B: N/A | NA | B: 8.9 | B: 10.3 | B: 14.7 |
| T: 55.3 | T: 59.8 | T: 55 | T: 52 | T: 56 | T: 58.2 | T: 56.1 | ||
| Nights with awakenings (%) | B: 13.3 | B: 22.6 | B: 21.8 | B: 31.1 | NA | B: 33.7 | B: 32.1 | B: 27.7 |
| T: 6.5 | T: 9.4 | T: 9.0 | T: 14.1 | T: 14.1 | T: 12.0 | T: 11.5 | ||
| Severe exacerbations (events/patient/year) | 0.08 | 0.23 | 0.19 | 0.19 | 0.24 | 0.24 | 0.25 | 0.22 |
*
24-hour period.
†
For weeks 0–4 (during which morning and evening budesonide/formoterol doses were unchanged at two inhalations of 200/6).
B, baseline; T, treatment; NA, not available; N/A, not applicable; SMART, single maintenance and reliever therapy.